Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2475741 | 1.00 | HTR6 (0.56) | HTR6FYNL3MBTL3L3MBTL1DPP4 | |
| SCHEMBL20365049 | 1.00 | HTR6 (0.56) | HTR6FYNL3MBTL3L3MBTL1DPP4 | |
| Hydrochloric Acid SCHEMBL7814587 | 0.97 | HTR6 (0.54) | HTR6FYNL3MBTL3L3MBTL1DPP4 | |
| Hydrochloric Acid SCHEMBL29082713 | 0.97 | HTR6 (0.54) | HTR6FYNL3MBTL3L3MBTL1DPP4 | |
| SCHEMBL3810047 | 0.97 | — | — | |
| Bromide SCHEMBL28560892 | 0.94 | HTR6 (0.56) | HTR6FYNL3MBTL3L3MBTL1DPP4 | |
| Hydrochloric Acid SCHEMBL22607680 | 0.94 | HTR6 (0.56) | HTR6FYNL3MBTL3L3MBTL1DPP4 | |
| Hydrochloric Acid SCHEMBL3258445 | 0.94 | HTR6 (0.56) | HTR6FYNL3MBTL3L3MBTL1DPP4 | |
| SCHEMBL3056808 | 0.91 | — | — | |
| SCHEMBL22737698 | 0.90 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1MBTD1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945801-B2 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| US-20100152171-A1 | CGRP Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-7700589-B2 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| EP-1558600-B1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-20070244099-A1 | CGRP Antagonists | RUDOLF KLAUS | 2007-10-18 | — | — | US | disclosed |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-04-13 | — | — | US | disclosed |
| EP-1558601-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| EP-1558600-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040132716-A1 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | US | disclosed |
| WO-2004037810-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037811-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244099-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | HTR6 307/4885FYN 3818/4885L3MBTL3 4478/4885 |
| US-20100152171-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | HTR6 307/4885FYN 3818/4885L3MBTL3 4478/4885 |
| US-20040132716-A1 | CGRP antagonists | OPRL1, HTR1D, CALCA | HTR6 179/4885FYN 4187/4885L3MBTL3 4549/4885 |
| US-11945801-B2 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | HTR6 649/4885FYN 2280/4885L3MBTL3 3913/4885 |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | HTR6 361/4885FYN 4296/4885L3MBTL3 4615/4885 |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | HTR6 361/4885FYN 4296/4885L3MBTL3 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.